PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.

[1][2][3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.

[4]

This analgesic-related article is a stub.

You can help Wikipedia by expanding it.